trial · primary record
Cadonilimab,Lenvatinib
Renal Cell Carcinoma (Kidney Cancer)
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 54 |
| Primary completion | 2028-03-01 |
| Primary endpoint | Objective Response Rate(ORR) |
| Registry ID | NCT07909265 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-02T15:47:04.352Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07909265
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.